» Articles » PMID: 27152762

Growth Factor Therapy Sequesters Inflammation in Affording Neuroprotection in Cerebrovascular Diseases

Overview
Specialties Neurology
Pharmacology
Date 2016 May 7
PMID 27152762
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In recent years, accumulating evidence has demonstrated the key role of inflammation in the progression of cerebrovascular diseases. Inflammation can persist over prolonged period of time after the initial insult providing a wider therapeutic window. Despite the acute endogenous upregulation of many growth factors after the injury, it is not sufficient to protect against inflammation and to regenerate the brain. Therapeutic approaches targeting both dampening inflammation and enhancing growth factors are likely to provide beneficial outcomes in cerebrovascular disease.

Areas Covered: In this mini review, we discuss major growth factors and their beneficial properties to combat the inflammation in cerebrovascular diseases. Emerging biotechnologies which facilitate the therapeutic effects of growth factors are also presented in an effort to provide insights into the future combination therapies incorporating both central and peripheral abrogation of inflammation. Expert commentary: Many studies discussed in this review have demonstrated the therapeutic effects of growth factors in treating cerebrovascular diseases. It is unlikely that one growth factor can be used to treat these complex diseases. Combination of growth factors and anti-inflammatory modulators may clinically improve outcomes for patients. In particular, transplantation of stem cells may be able to achieve both goals of modulating inflammation and upregulating growth factors. Large preclinical studies and multiple laboratory collaborations are needed to advance these findings from bench to bedside.

Citing Articles

Neuro-regeneration or Repair: Cell Therapy of Neurological Disorders as A Way Forward.

Song X, Fan C, Rahman A, Choudhary M, Wang X Curr Neuropharmacol. 2024; 22(14):2272-2283.

PMID: 38939990 PMC: 11451317. DOI: 10.2174/1570159X22666240509092903.


An update on stem cell therapy for stroke patients: Where are we now?.

Gordon J, Borlongan C J Cereb Blood Flow Metab. 2024; 44(9):1469-1479.

PMID: 38639015 PMC: 11418600. DOI: 10.1177/0271678X241227022.


Induced Inflammatory and Oxidative Markers in Cerebral Microvasculature by Mentally Depressive Stress.

Zhu Y, Haddad Y, Yun H, Geng X, Ding Y Mediators Inflamm. 2023; 2023:4206316.

PMID: 36852396 PMC: 9966573. DOI: 10.1155/2023/4206316.


Sufentanil alleviates cerebral ischemia-reperfusion injury by inhibiting inflammation and protecting the blood-brain barrier in rats.

Wang Z, Du X, Yu D, Yang Y, Ma G, Jia X Eur J Histochem. 2022; 66(1).

PMID: 35016494 PMC: 8764464. DOI: 10.4081/ejh.2022.3328.


Amazon rainforest rodents (Proechimys) are resistant to post-stroke epilepsy.

Ortiz-Villatoro N, Reyes-Garcia S, Freitas L, Rodrigues L, Santos L, Faber J Sci Rep. 2021; 11(1):16780.

PMID: 34408211 PMC: 8373885. DOI: 10.1038/s41598-021-96235-5.


References
1.
Mowla S, Farhadi H, Pareek S, Atwal J, Morris S, Seidah N . Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem. 2001; 276(16):12660-6. DOI: 10.1074/jbc.M008104200. View

2.
Notaras M, Hill R, van den Buuse M . A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. Neurosci Biobehav Rev. 2015; 51:15-30. DOI: 10.1016/j.neubiorev.2014.12.016. View

3.
Liu X, Gonzalez-Toledo M, Fagan A, Duan W, Liu Y, Zhang S . Stem cell factor and granulocyte colony-stimulating factor exhibit therapeutic effects in a mouse model of CADASIL. Neurobiol Dis. 2014; 73:189-203. DOI: 10.1016/j.nbd.2014.09.006. View

4.
Schier A . Chemokine signaling: rules of attraction. Curr Biol. 2003; 13(5):R192-4. DOI: 10.1016/s0960-9822(03)00122-2. View

5.
Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A . Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 2014; 127(6):861-79. PMC: 4034750. DOI: 10.1007/s00401-014-1256-4. View